Cytosorbents Current Deferred Revenue vs Capital Surpluse Analysis
CTSO Stock | USD 0.92 0.06 6.12% |
Cytosorbents Crp financial indicator trend analysis is way more than just evaluating Cytosorbents Crp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cytosorbents Crp is a good investment. Please check the relationship between Cytosorbents Crp Current Deferred Revenue and its Capital Surpluse accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.
Current Deferred Revenue vs Capital Surpluse
Current Deferred Revenue vs Capital Surpluse Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cytosorbents Crp Current Deferred Revenue account and Capital Surpluse. At this time, the significance of the direction appears to have strong relationship.
The correlation between Cytosorbents Crp's Current Deferred Revenue and Capital Surpluse is 0.64. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Cytosorbents Crp, assuming nothing else is changed. The correlation between historical values of Cytosorbents Crp's Current Deferred Revenue and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Cytosorbents Crp are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Current Deferred Revenue i.e., Cytosorbents Crp's Current Deferred Revenue and Capital Surpluse go up and down completely randomly.
Correlation Coefficient | 0.64 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Capital Surpluse
Most indicators from Cytosorbents Crp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cytosorbents Crp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.At this time, Cytosorbents Crp's Selling General Administrative is very stable compared to the past year. As of the 21st of May 2024, Issuance Of Capital Stock is likely to grow to about 17.5 M, while Tax Provision is likely to drop (854.4 K).
2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 62.9M | 60.9M | 66.9M | 70.2M | Total Revenue | 40.1M | 29.4M | 36.3M | 38.2M |
Cytosorbents Crp fundamental ratios Correlations
Click cells to compare fundamentals
Cytosorbents Crp Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cytosorbents Crp fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 27.4M | 90.0M | 89.5M | 63.2M | 53.3M | 55.9M | |
Short Long Term Debt Total | 16.1M | 1.0M | 13.8M | 18.3M | 18.3M | 19.2M | |
Total Current Liabilities | 9.9M | 10.2M | 13.7M | 9.7M | 14.5M | 15.3M | |
Net Debt | 3.9M | (70.4M) | (38.3M) | (3.9M) | 4.2M | 4.4M | |
Retained Earnings | (188.8M) | (196.6M) | (221.2M) | (254.0M) | (282.5M) | (268.4M) | |
Cash | 12.2M | 71.4M | 52.1M | 22.1M | 14.1M | 13.2M | |
Common Stock Total Equity | 32.6K | 43.2K | 43.5K | 43.6K | 39.3K | 51.6K | |
Common Stock Shares Outstanding | 32.3M | 38.8M | 43.4M | 43.6M | 44.7M | 46.9M | |
Liabilities And Stockholders Equity | 27.4M | 90.0M | 89.5M | 63.2M | 53.3M | 55.9M | |
Total Liab | 24.0M | 10.7M | 26.9M | 27.9M | 30.0M | 31.5M | |
Property Plant And Equipment Gross | 3.0M | 3.1M | 18.6M | 23.3M | 25.2M | 26.4M | |
Total Current Assets | 20.9M | 82.5M | 64.3M | 33.8M | 25.7M | 17.6M | |
Accumulated Other Comprehensive Income | 526.0K | (1.7M) | 525.6K | 2.3M | 529.3K | 555.8K | |
Other Current Liab | 5.6M | 6.8M | 8.2M | 6.3M | 6.5M | 6.8M | |
Total Stockholder Equity | 3.4M | 79.2M | 62.6M | 35.4M | 23.3M | 12.9M | |
Property Plant And Equipment Net | 3.0M | 3.1M | 18.6M | 23.3M | 22.1M | 23.2M | |
Non Current Assets Total | 6.5M | 7.5M | 25.2M | 29.5M | 27.6M | 28.9M | |
Cash And Short Term Investments | 12.2M | 71.4M | 52.1M | 22.1M | 14.1M | 14.1M | |
Non Current Liabilities Total | 14.0M | 582K | 13.3M | 18.1M | 15.4M | 16.2M | |
Other Stockholder Equity | 191.6M | 277.5M | 283.2M | 287.0M | 305.2M | 160.4M | |
Common Stock | 32.6K | 43.2K | 43.5K | 43.6K | 54.2K | 53.5K | |
Accounts Payable | 2.0M | 1.8M | 2.8M | 1.7M | 3.8M | 4.0M | |
Non Currrent Assets Other | 3.5M | 4.3M | 1.9M | 1.7M | (3.7M) | (3.5M) | |
Other Current Assets | 2.1M | 3.2M | 2.9M | 2.5M | 1.8M | 1.1M | |
Good Will | 1.8M | 2.6M | 3.4M | 4.2M | 4.9M | 5.1M | |
Intangible Assets | 3.4M | 4.2M | 4.7M | 4.4M | 3.9M | 4.1M | |
Other Assets | 123.5K | 5.4M | 6.6M | 1.7M | 2.0M | 1.1M | |
Property Plant Equipment | 3.0M | 2.1M | 18.6M | 10.7M | 12.4M | 13.0M | |
Long Term Debt | 6.0M | 9.3M | 13.4M | 5M | 2.5M | 3.8M | |
Net Receivables | 4.5M | 5.2M | 4.5M | 5.7M | 6.1M | 6.4M | |
Retained Earnings Total Equity | (188.8M) | (196.6M) | (221.2M) | (254.0M) | (228.6M) | (217.2M) | |
Inventory | 2.1M | 2.7M | 4.8M | 3.5M | 3.7M | 1.9M | |
Short Term Debt | 2.1M | 447K | 571K | 109K | 2.9M | 3.0M | |
Net Tangible Assets | 56.6K | 79.2M | 62.6M | 35.4M | 40.7M | 23.3M | |
Capital Surpluse | 191.6M | 277.5M | 283.2M | 287.0M | 330.1M | 215.6M | |
Short Long Term Debt | 4M | 666.7K | 1.7M | 2.5M | 2.9M | 1.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Cytosorbents Stock analysis
When running Cytosorbents Crp's price analysis, check to measure Cytosorbents Crp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytosorbents Crp is operating at the current time. Most of Cytosorbents Crp's value examination focuses on studying past and present price action to predict the probability of Cytosorbents Crp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytosorbents Crp's price. Additionally, you may evaluate how the addition of Cytosorbents Crp to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is Cytosorbents Crp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share 0.814 | Quarterly Revenue Growth (0.08) | Return On Assets (0.32) | Return On Equity (0.97) |
The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.